Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Expanded FDA Lab Oversight May Result In Relaxed Regs For Some Test Kits

This article was originally published in The Gray Sheet

Executive Summary

FDA is considering changing how it regulates in vitro diagnostic test kits, perhaps down-classifying some kits, as it prepares to assume oversight of laboratory-developed-test services

You may also be interested in...



Clinical Labs Join Medical Device User Fee Negotiations

The clinical lab community will for the first time join traditional device and imaging equipment makers in FDA user fee reauthorization talks, but members are not quite ready to concede to agency oversight.

Clinical Labs Join Medical Device User Fee Negotiations

The clinical lab community will for the first time join traditional device and imaging equipment makers in FDA user fee reauthorization talks, but members are not quite ready to concede to agency oversight.

AdvaMed Compiles List Of Tests That Should Be Exempt From FDA Review

Device trade group AdvaMed has given FDA a list of 30 lower-risk diagnostic tests that it says should be exempt from pre-market review

Related Content

Topics

UsernamePublicRestriction

Register

MT029167

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel